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Abstract 
Purpose: Accurate recording of immunisation status is essential for the evaluation of any 
immunization program.  In September 2006, 7 Valent Pneumococcal Conjugate 
Vaccination (PCV7) was introduced into the UK’s routine childhood immunisation 
programme.  This study validated the PCV7 immunization status of children aged 2 years 
recorded in the IMS Disease Analyses database.  
 
Methods: The PCV7 vaccination uptake rate for children born in 2008 in the IMS DA 
database was calculated.  A sample of 173 of the 2497 children not recorded as vaccinated 
was identified and a questionnaire was sent to each of their General Practitioners to 
ascertain the child’s true PCV7 vaccination status.  
 
Results: In the IMS DA data of 15,237 children born in 2008, 12,740 (83.6%) had a 
vaccination record of PCV7. One hundred and eleven of the 167 questionnaires sent to the 
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child’s general practitioners were returned, giving an adjusted response rate of 111/167 
(66.5%).  Based on the general practitioners’ responses, 71 (64%) of these children were 
fully vaccinated according to their General Practitioner’s records making the revised 
estimated vaccination rate for this cohort 94.1% 
  
Conclusion: This validation study has shown that caution is needed if using historical IMS 
patient-level data to analyse the effectiveness of PCV7 as there is a potential under-
recording of immunization leading to underrepresentation of vaccination rates by 
approximately ten per cent. Coverage of other vaccines may also be underestimated in the 
IMS database.   
 
Introduction 
Childhood immunization against infectious diseases is a key component of preventive health 
care.  In September 2006, 7 Valent Pneumococcal Conjugate Vaccination (PCV7) was 
introduced into the UK routine childhood immunization programme at two and four months of 
age, with a booster dose after 12 months of age. 1 To evaluate its impact and effectiveness 
on child health, it is important to have an accurate measure of uptake that can be used to 
investigate the association between the incidence of pneumococcal infections and PCV7 
(Prevnar 7®) usage. One possible source of data on immunisation uptake is the IMS 
Disease Analyser (IMS DA).  It is a private, international health care company which gathers 
anonymized data from a nationally representative sample of UK general practices.2   The 
data gathered from the sampled practices are used to calculate projected national 
vaccination coverage.   In this study the accuracy of IMS-DA summary statistics of 
vaccination uptake was ascertained by comparing patient-level data from the database with 
the immunization status reported by the General Practitioner after reviewing the individual’s 
health record. 
 
Methods 
Study design  
This cross sectional observational study was designed to investigate the actual immunisation 
status of children with no record of having received PCV7 the IMS DA database. 
 
Data source 
The IMS Disease Analyzer (IMS-DA) (formally known as Mediplus) derives anonymised data 
from the electronic health records of approximately three million patient registered with over 
500 general practitioners working in 125 general practices throughout the UK. Automatically 
downloaded data includes demographic characteristics, diagnoses, and prescriptions. Drugs 
are coded based on the Anatomical Therapeutic Chemical (ATC) classification and the Read 
codes used in UK General Practice for symptoms and diagnoses are mapped to ICD-10 
(International Statistical Classification Disease, 10th Revision) by the IMS Health team.3   
 
Source population  
The target population were children born in 2008.  A list was compiled of children who by the 
age of two had no record of a PCV7 record in the IMS DA database.  This list was compiled 
by identifying those who had no event or prescription codes corresponding to pneumococcal 
vaccination (Read codes listed in Table 1 or ATC code J07A7).  A computer generated 
random sample of 173 apparently unvaccinated children was made and in December 2010 a 
letter and one page questionnaire, with the child’s age, gender, date of birth and patient ID, 
was sent by IMS-DA to the relevant GP asking them to review the child’s health record and 
report if they had received Prevnar 7® vaccine and which of the three doses they had been 
given.  The general practitioner received £15 for completion of the questionnaire. 
 
Sample size estimation for questionnaire study 
The sample size was based on some preliminary work with IMS DA data indicating that of 
the  approximately 18,000 children aged 0-2 years registered approximately 3600 (15%) did 
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not have any coded record of PCV7 immunisation. Assuming that 5% of these children were 
immunised but unrecorded, the sample size needed to detect this with 95% confidence 
would be 132 patients (OpenEpi, Version 3, open source calculator—SSPropor).  We 
recognised that it was unlikely to get data on every child so the sample was increased to 
173, allowing for a 25% none-response rate. 
 
Ethical approval 
This protocol for this study was approved by the IMS Independent Scientific and Ethical 
Advisory Committee on 10th October 2008. 
 
Results 
The IMS DA database identified 15,237 children born in 2008, of these 12,740 (83.6%) had 
a coded record of PCV7 vaccination (Figure 1).  A random sample of 173 was taken from the 
2,497 children with no vaccination record.  Six children could not be followed up as their 
practice had stopped contributing data to IMS DA (n=1) and another practice encountered a 
technical problem (n=5). Out of 167 questionnaires sent to the children’s’ general 
practitioners, 111 questionnaires were returned, giving an adjusted response rate of 111/167 
(66.5%).  Based on the general practitioners’ responses 71/111 (64.0%) were fully 
vaccinated (3 doses of PCV7 given), 3/111 (2.7%) partially vaccinated (only 1 or 2 doses 
given), 28/111 (25.2%) were unvaccinated and for 9/111 (8.1%) their vaccination status was 
unknown (Figure 1).  
 
Extrapolating these observations from our subsample of 111 children to the IMS DA cohort 
would mean that an extra 1597 children had been fully vaccinated with PCV7, 68 partially 
vaccinated, 630 unvaccinated and for 202 children their vaccination status was unknown.   
Thus the percentage of fully vaccinated children within this cohort becomes 94.1% 
(14337/15237), rather than 83.6%.  
 
The worst case scenario would be if all of the children for whom we had no response from 
their GPs were unprotected.  If we adjust for this potential response bias in our estimate, and 
combine these children with those who were only partially vaccinated or for whom 
vaccination status was unknown, it yields a minimum vaccination rate of 90.6%.  
 
Discussion  
Of the 111 children with no PCV7 record in the IMS selected data for whom we were able to 
validate their vaccination status , 71/111 (64.0%) of these had in fact been fully vaccinated 
with  PCV7.   This indicates that the IMS vaccination data is incomplete and therefore 
underestimates the vaccine coverage. The uptake rate of PCV7 would appear to be at least 
90.6%, and possibly as high as 94.1%, not the 83.6% originally estimated from IMS DA 
database.  
 
These higher vaccination rates comply more closely with other sources of data on 
immunization uptake, including Cover of Vaccination Evaluated Rapidly (COVER).  This 
scheme was established in 1987 to monitor immunization coverage of children aged 1, 2 and 
5 years of age3. COVER statistics are compiled by Public Health England by extracting 
vaccine coverage data each quarter from all child health information systems throughout the 
country.  COVER national statistical data for 2010-2011 estimated the vaccine (PCV7) 
coverage reached approximately 94% children by their first birthday.4  
 
Why might there be this degree of under reporting of vaccination uptake in database 
analysis?  One can only speculate, but possible explanations include no access to the 
patients’ electronic health record at the time of immunization, lack of triggers to enter vaccine 
administration on the electronic health record  (for example, the vaccine is available in 
practice without the need for personalized prescription).  The data may also sometimes be 
entered into the electronic health record as a free text entry rather than Read coded and this 
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means it is not recognized in routine searches and retrieval.  The fee General Practices are 
paid for each immunization administered might theoretically incentivize the recording child 
immunization, but the payment is small, its existence may not be apparent to staff 
uninvolved with the financial and business aspects of the practice, and it rarely impacts on 
the income of salaried staff. 5, 6 Problems with the computer system has been highlighted as 
a barrier to fully implementing pneumococcal immunization programs in a previous study.5   
Additionally, immunization has never been included as an indicator of quality in the Quality 
and Outcomes Framework (QOF) scheme which has achieved better documentation and 
some improved clinical care in other areas of health.7 
 
What are the clinical implications of our research?  Although this work focused only on PCV7 
immunization it is likely to be relevant to all the other childhood immunization programs, 
including influenza, measles, mumps and rubella (MMR), rotavirus vaccine and meningitis B 
& C vaccine.  A multifaceted approach is needed to improve the completeness and 
standardization of the recording of vaccination in the primary care electronic health record. 
This will include ensuring relevant members of the primary care team, including health 
visitors and school nurses can, and do, access the child’s EHR for timely entry of data.  
Vigilance is also required to ensure that when vaccines are administered in a setting other 
than primary care, for example in a hospital setting or private health care facility, that the 
child’s general practitioner is informed so that the information can be entered into the child’s 
EHR.  With such changes the completeness of databases derived from the primary care 
EHR will be improved and IMS DA will be able to offer more valid data that can be used in 
the evaluation of vaccination coverage and also to investigate the impact of vaccines on 
specific disease prevention. 
 
Strength & limitations  
The major strength of our study is that the IMS Disease Analyser uses data broadly 
representative of the UK population in terms of age and gender, although there is under 
representation of smaller practices and of practices in Scotland and Northern Ireland2.  This 
is the first study to validate immunization statistic estimates from the IMS DA. The limitation 
of the study is that it focused only on underreporting; no attempt was made to confirm the 
validity of positive coding of vaccination.  A third of GPs did not respond to the enquiry, and 
there is a risk that there may be responder bias with the practitioners of unvaccinated 
children being less likely to respond.  This was recognised in our calculation of the worst 
case scenario.    
 
Conclusions 
This validation study has demonstrated that individual patient-level data analyses based on 
IMS data cannot reliably be employed to investigate the association between PCV7 
vaccination and the incidence of pneumococcal infection diseases.   
 
The under reporting of vaccination in IMS data arises because of failure to routinely code all 
childhood immunizations in the primary care electronic health record, and we need to better 
understand the challenges encountered in practice.  
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Figure 1: Questionnaire Responses        
 
                                 
 
 
 
15,237 children born in 2008 in IMS DA database 
2497 (16.4%) children with no record of PCV7 
vaccination 
 
12,740 children (83.6%) with record of PCV7 
vaccination 
 
173 apparently 
unvaccinated children 
sampled from IMS DS 
database (6.9% sample) 
6 children removed by IMS (6 questionnaires 
could not be completed) 
1 practice encountered a technical problem 
(n=5)  
1 practice had left panel (n=1) 
 
167 questionnaires sent to 
child’s general practitioner  
56 (33.5%) questionnaires not returned  
 
                                    111 questionnaires returned (66.5%) 
71 (64.0%) children 
fully vaccinated with 
PCV7  
(i.e. 1st, 2nd & 3rd doses 
recorded) 
 
3 (2.7%) children 
partially vaccinated 
 1st dose only (n=1) 
 2nd & 3rd doses (n=1) 
 1st & 2nd doses (n=1) 
 
9 (8.1%) children for 
whom vaccination status 
was unknown 
Because of problem with 
identification (n=1), 
moved away (n=4), 
technical problem with 
decryption (n=4) 
 
28 (25.2%) children not 
vaccinated with PCV7   
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Table 1: Read 4 and Read 5 codes used in IMS DA database search to identify those two 
year old children who had received pneumococcal vaccination  
 
READ_4or5_CODE READ_4or5_TEXT     
65720 Pneumococcal vaccination  
given 
    
.9Oo. Pneumococcal vaccination 
admin 
    
.6572 Pneumococcal vaccination     
.n4b. Pneumococcal vaccine      
.68Ne Consent pneumococcal 
vaccine 
    
.657K Booster pneumococcal 
vaccinate 
    
.Q5AC Adv reac: pneumococcal 
vaccine 
    
.657N 3rd pneumococcal conjug 
vaccine 
    
.657M 2nd pneumococcal conjug 
vaccine 
    
.657L 1st pneumococcal conjug 
vaccine 
    
 
 
 
 
 
 
 
 
 
